Systemic inflammation tracks with drug-resistant epilepsy in Ghanaian children
Childhood drug-resistant epilepsy carries a heavy clinical burden, and this Ghanaian cohort places systemic inflammation closer to the center of the discussion. In a cross-sectional study of 180 children at a tertiary hospital, investigators compared 60 children with drug-resistant epilepsy, 60 with controlled epilepsy, and 60 healthy controls at a single time point. The biologic signal was consistent: children with drug-resistant epilepsy had higher neutrophil-to-lymphocyte ratio, higher chemokine (C-C motif) ligand 11, and higher prostaglandin E2 than the control groups. Those markers did not drift upward casually; they separated the drug-resistant group from both children with controlled epilepsy and healthy participants in a way that suggests a broader inflammatory phenotype.
A one-time blood draw cannot prove causality, but it can identify a pattern worth taking seriously at the bedside.
The clinical question here is not whether epilepsy is driven only by inflammation. It is whether systemic immune activation helps mark, amplify, or accompany the subgroup of children whose seizures persist despite treatment. That distinction matters because drug resistance often reflects more than medication choice alone. It may point to altered neuronal excitability, blood-brain barrier dysfunction, immune signaling, or a seizure biology that is less responsive to standard antiseizure therapy. In that context, the elevation of NLR, CCL11, and PGE2 is not just a laboratory curiosity; it may represent a measurable footprint of a more refractory disease state.
Biomarker separation was strongest for CCL11
The regression results were striking, especially for CCL11. Using standardized continuous factors in Firth penalized logistic regression, higher NLR was independently associated with drug-resistant epilepsy with an adjusted odds ratio of 7.31 (95% CI 2.00–26.63). CCL11 showed the largest association, with an adjusted odds ratio of 54.97 (95% CI 8.91–339.25). PGE2 also remained independently associated, with an adjusted odds ratio of 2.51 (95% CI 1.05–5.96). These are wide confidence intervals, especially for CCL11, but the direction of effect was coherent across markers.
The biology behind these markers is plausible. NLR captures a balance between neutrophil-driven innate immune activity and lymphocyte-mediated adaptive regulation, a crude but useful signal of systemic inflammatory tone. CCL11, also known as eotaxin-1, participates in chemotaxis and immune-cell trafficking, and its association with seizure refractoriness raises the possibility that peripheral immune signaling may mirror or influence central nervous system inflammation. PGE2 sits even closer to classic inflammatory physiology. It is a prostaglandin with known roles in pain, fever, and inflammatory signaling, and in the epileptic brain it may contribute to excitability through pathways that are still being defined.
The study design does not allow a direct claim that these mediators cause resistance to antiseizure medication. It does show that children with drug-resistant epilepsy had a different systemic inflammatory profile than children whose seizures were controlled.
Seizure severity signals weakened after drug resistance was considered
The investigators also examined seizure severity using NHS3 seizure-severity scores. In pooled analyses, the inflammatory markers were associated with those scores. Once drug-resistant status entered the model, however, those relationships became substantially attenuated. The pattern suggests that the apparent link between inflammation and severity may be largely driven by the presence of drug-resistant epilepsy itself. In practical terms, the inflammatory signature may be less a standalone severity meter and more a biomarker cluster tied to the subgroup with refractory disease.
That result narrows the clinical reading of the data. It argues against a simplistic model in which higher inflammation merely equals worse seizures across the entire pediatric epilepsy spectrum. Instead, the inflammatory markers seem to separate a biologically distinct phenotype: the child whose epilepsy is resistant to standard treatment and whose seizure burden is likely to be more difficult to control over time. For clinicians, that raises the possibility that immune biomarkers could eventually complement seizure history, medication response, and electroclinical assessment when estimating risk.
The Ghanaian cohort adds local evidence to a broader question
Evidence linking inflammation and epilepsy has been building in different settings, but data from low- and middle-income countries remain limited. This study adds local clinical experience from Ghana, where access to specialist epilepsy care, diagnostic resources, and longitudinal biomarker studies can be constrained. The hospital-based design captured children already under tertiary care, which makes the cohort clinically relevant but also introduces selection effects that matter when interpreting the findings. Children seen at a referral center are often the ones with the most complex disease, the most persistent seizures, or the greatest concern from families and clinicians.
Even with those limitations, the signal was not subtle. The separation between drug-resistant epilepsy and the comparison groups was seen across multiple inflammatory measures, not just one isolated assay. That pattern strengthens the case for further work. Future prospective studies will need to determine whether these biomarkers rise before drug resistance becomes obvious, whether they track response to treatment changes, and whether they retain value after accounting for infection, malnutrition, intercurrent illness, and other factors that can also shape inflammatory markers in children.
What the findings can and cannot support today
For now, the most defensible reading is straightforward: selected systemic inflammatory markers were associated with drug-resistant pediatric epilepsy in this Ghanaian cohort, and the association persisted in adjusted models. The study does not justify routine biomarker-guided treatment, and it does not establish that anti-inflammatory therapy would improve seizure control. It does, however, strengthen the argument that refractory childhood epilepsy may have an immunologic dimension that deserves prospective study.
That question is clinically important because seizure persistence in childhood affects cognition, schooling, family function, and long-term neurological development. If inflammation helps define a more treatment-refractory subgroup, then biomarker research could eventually inform earlier recognition of difficult epilepsy, better risk stratification, and more targeted therapeutic trials. The next step is not speculation alone. It is longitudinal validation in larger pediatric cohorts, with repeated sampling and careful clinical phenotyping, to see whether these inflammatory markers simply accompany drug resistance or help predict it before the trajectory becomes fixed.